Abstract: The subject matter disclosed herein is directed to particles containing phospholipids and/or fatty acids and the uses thereof for treating autoimmune diseases, inflammatory diseases and for modulating immune and inflammatory responses. Methods of preparing the particles are also described.

Abstract: A method and system for combination therapy utilizing local drug delivery and radiotherapy at a target site of body tissue are provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A cargo may be delivered to the target site when exposed to the localized electric field. Radiotherapy is applied to the target site in combination with the local drug delivery.

Abstract: Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.

Abstract: Compositions comprising decitabine and tetrahydrouridine for the treatment of blood disorders and hematological and solid malignancies are described.

Abstract: A delivery system for local drug delivery to a target site of internal body tissue is provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A reservoir is configured to be disposed such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field. Associated methods are also provided.

Abstract: The present invention provides a system for fabricating a microneedle device and microneedle devices. The system includes depositing a first material on a delivery sheet, introducing the delivery sheet with deposited first material to a mold, passing the delivery sheet with deposited first material and mold through a nip-point to introduce at least a portion of first material into cavities in the mold, and separating the mold from the first material to provide a microneedle device with needles mimicking the cavities of the mold.

Abstract: Disclosed herein are geometrically engineered particles having varied shapes and sizes and surface charge which can incorporate drugs and/or other biomaterials for targeted delivery, such as pulmonary delivery. The size, shape, etc. of a particle can be designed and corresponding particles can be prepared that target or de-target immunological responses to the particles themselves, for example, the response of alveolar macrophages. Methods of modulating immune responses by utilizing the particles are also disclosed. The particles can be composed substantially of therapeutic, drug and polymer or can comprise polymers and proteins. The particles may also be composed of diagnostic agents and additional biomaterials to confer aerosolization and cellular uptake properties. The particles also may have a range of physical features such as fenestrations, angled arms, asymmetry and surface roughness, charge which alter the interactions with cells and tissues.

Abstract: The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C?O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material.

Abstract: Delivery systems adapted for implementation during a brachytherapy procedure are provided. The delivery system includes a plurality of brachytherapy seeds and a plurality of spacers. Each spacer is formed of a matrix material carrying a plurality of microparticles and/or nanoparticles. The microparticles and/or nanoparticles carry an agent and are biodegradable and/or biocompatible. The brachytherapy seeds and the spacers are configured to be delivered to a target site. Associated methods are also provided.

Abstract: Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.

Abstract: A delivery system for local drug delivery to a target site of internal body tissue is provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A reservoir is configured to be disposed such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field. Associated methods are also provided.

Abstract: Compositions comprising decitabine and tetrahydrouridine for the treatment of blood disorders and hematological and solid malignancies are described.

Abstract: A method of and system for generating a speech signal with an overlayed random frequency signal using prosody modification of a speech signal output by a text-to-speech (TTS) system to substantially prevent an interactive voice response (IVR) system from understanding the speech signal without significantly degrading the speech signal with respect to human understanding. The present invention involves modifying a prosody of the speech output signal by using a prosody of the user's response to a prompt. In addition, a randomly generated overlay frequency is used to modify the speech signal to further prevent the IVR system from recognizing the TTS output. The randomly generated frequency may be periodically changed using an overlay timer that changes the random frequency signal at a predetermined intervals.

Abstract: The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C?O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material.

Abstract: A method of and system for generating a speech signal with an overlayed random frequency signal using prosody modification of a speech signal output by a text-to-speech (TTS) system to substantially prevent an interactive voice response (IVR) system from understanding the speech signal without significantly degrading the speech signal with respect to human understanding. The present invention involves modifying a prosody of the speech output signal by using a prosody of the user's response to a prompt. In addition, a randomly generated overlay frequency is used to modify the speech signal to further prevent the IVR system from recognizing the TTS output. The randomly generated frequency may be periodically changed using an overlay timer that changes the random frequency signal at a predetermined intervals.

Abstract: A method and apparatus utilizing prosody modification of a speech signal output by a text-to-speech (TTS) system to substantially prevent an interactive voice response (IVR) system from understanding the speech signal without significantly degrading the speech signal with respect to human understanding. The present invention involves modifying the prosody of the speech output signal by using the prosody of the user's response to a prompt. In addition, a randomly generated overlay frequency is used to modify the speech signal to further prevent an IVR system from recognizing the TTS output. The randomly generated frequency may be periodically changed using an overlay timer that changes the random frequency signal at a predetermined intervals.

Abstract: Methods of making fluoropolymers from at least one fluoromonomer in either (1) a heterogeneous medium comprising a carbon dioxide and an aqueous phase with or without hydrocarbon surfactants or dispersants or stabilizer, or (2) a homogenous medium containing carbon dioxide with one or more organic solvents, are described.

Abstract: A method for forming a fluoropolymer comprises providing a reaction mixture comprising carbon dioxide, at least one fluoromonomer, and an initiator; and reacting the at least one fluoromonomer in the reaction mixture to form a fluoropolymer. The fluoropolymer has a multimodal molecular weight distribution.

Abstract: The presently disclosed subject matter provides functional perfluoropolyether (PFPE) materials for use in fabricating and utilizing microscale devices, such as a microfluidic device. The functional PFPE materials can be used to adhere layers of PFPE materials to one another or to other substrates to form a microscale device. Further, the presently disclosed subject matter provides a method for functionalizing the interior surface of a microfluidic channel and/or a microtiter well. Also the presently disclosed subject matter provides a method for fabricating a microscale structure through the use of a sacrificial layer of a degradable material.

Abstract: Discrete micro and nanoscale particles are formed in predetermined shapes and sizes and predetermined size dispersions. The particles can also be attached to a film to form arrays of particles on a film. The particles are formed from molding techniques that can include high throughput and continuous particle molding.